BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Show more...
CEO
Mr. Roberto Francesco Bellini
従業員
40
国
カナダ
ISIN
CA07987C2040
WKN
000A2PQKK
上場銘柄
0 Comments
意見をシェア
FAQ
Bellus Healthの株価は今日いくらですか?▼
BLU.TO の現在価格は C$19.48 CAD で、過去24時間で -0.1% 下落しました。チャートで Bellus Health 株価の動きを詳しく確認しましょう。